Eisenbarth George S
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Mail Stop B140, P.O. Box 6511, Aurora, Colorado 80045-6511, USA.
J Clin Endocrinol Metab. 2007 Jul;92(7):2403-7. doi: 10.1210/jc.2007-0339.
Type 1 diabetes is a heterogeneous disorder characterized by severe beta-cell loss. The great majority of patients have type 1A or immune-mediated diabetes.
There has been recent progress in defining the genetics, pathogenesis, and natural history of the disease. In addition, there is a major effort to develop immunotherapies to prevent the disorder and to cure the disease with islet transplantation, and there is potential for dramatic improvement in care with introduction of continuous glucose monitoring devices. The discovery of "metabolic memory" underscores the importance of excellent metabolic control. With comprehensive care, major microvascular complications (e.g. blindness and renal failure) are preventable for most patients.
The existence of multiple "competing" technologies to deal with this devastating disorder holds promise of improved outcomes.
1型糖尿病是一种以严重β细胞丧失为特征的异质性疾病。绝大多数患者患有1A型或免疫介导性糖尿病。
近期在明确该疾病的遗传学、发病机制和自然史方面取得了进展。此外,人们正在大力研发免疫疗法以预防该疾病,并通过胰岛移植治愈该疾病,而且引入连续血糖监测设备有可能显著改善治疗效果。“代谢记忆”的发现凸显了良好代谢控制的重要性。通过综合治疗,大多数患者可预防主要的微血管并发症(如失明和肾衰竭)。
存在多种应对这种破坏性疾病的“竞争性”技术,有望改善治疗结果。